» Articles » PMID: 24488880

How the TP53 Family Proteins TP63 and TP73 Contribute to Tumorigenesis: Regulators and Effectors

Overview
Journal Hum Mutat
Specialty Genetics
Date 2014 Feb 4
PMID 24488880
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

In mammals, the p53 family comprises two additional members, p63 and p73 (hereafter referred to as TP53, TP63, and TP73, respectively). The usage of two alternative promoters produces protein variants either with (transactivating [TA] isoforms) or without (ΔN isoforms) the N-terminal transactivation domain (TAD). In general, the TA proteins exert TP53-like tumor-suppressive activities through their ability to activate a common set of target genes. The ΔN proteins can act as dominant-negative inhibitors of the transcriptionally active family members. Additionally, they possess intrinsic-specific biological activities due to the presence of alternative TADs, and as a result of engaging a different set of regulators. This review summarizes the current understanding of upstream regulators and downstream effectors of the TP53 family proteins, with particular emphasis on those that are relevant for their role in tumorigenesis. Furthermore, we highlight the existence of networks and cross-talks among the TP53 family members, their modulators, as well as the transcriptional targets.

Citing Articles

p63: A Master Regulator at the Crossroads Between Development, Senescence, Aging, and Cancer.

Sadu Murari L, Kunkel S, Shetty A, Bents A, Bhandary A, Rivera-Mulia J Cells. 2025; 14(1.

PMID: 39791744 PMC: 11719615. DOI: 10.3390/cells14010043.


DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

Liu L, Gong D, Sun H, Feng F, Xu J, Sun X Front Immunol. 2024; 15:1470328.

PMID: 39380995 PMC: 11459316. DOI: 10.3389/fimmu.2024.1470328.


Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.

Tang M, Zhang Z, Wang P, Zhao F, Miao L, Wang Y Acta Pharm Sin B. 2024; 14(8):3457-3475.

PMID: 39220884 PMC: 11365446. DOI: 10.1016/j.apsb.2024.04.034.


Genetic Variants in p53 Pathway Genes Affect Survival of Patients with HBV-Related Hepatocellular Carcinoma.

Qin L, Qiu M, Tang J, Liu S, Lin Q, Huang Q J Hepatocell Carcinoma. 2024; 11:1541-1555.

PMID: 39156673 PMC: 11328861. DOI: 10.2147/JHC.S459792.


Comprehensive machine learning-based integration develops a novel prognostic model for glioblastoma.

Jiang Q, Yang X, Deng T, Yan J, Guo F, Mo L Mol Ther Oncol. 2024; 32(3):200838.

PMID: 39072291 PMC: 11278295. DOI: 10.1016/j.omton.2024.200838.